Biotech company AtheroNova today announced Fred Knoll, the principal and portfolio manager of Knoll Capital Management, as the newest member to the board of directors of AtheroNova.
Knoll has served in his current position at Knoll Capital since 1987, and was previously employed as an investment manager for General American Investors; was the U.S. representative on investments in leveraged buyouts and venture capital for Murray Johnstone Ltd. of Glasgow, UK; and was head of the New York investment group of UK-based Robert Fleming Inc., which was acquired by JP Morgan.
"As a leading investment manager, Fred brings a wealth of knowledge in emerging growth companies and will bring his expertise to our many opportunities as we transition into the next phase of clinical development at AtheroNova," Thomas W. Gardner, CEO of AtheroNova stated in the press release. "We welcome Fred to our board and look forward to working together as we develop AtheroNova's atherosclerosis regression and lipid modulation technology."
Knoll holds a Bachelor of Science in electrical engineering and computer science from Massachusetts Institute of Technology (MIT.), a Bachelor of Science in management from the Sloan School at MIT, and an MBA from Columbia University in finance.
AtheroNova operates through its wholly owned subsidiary, AtheroNova Operations, to focus on the discovery, research, development, and licensing of novel compounds to reduce or regress atherosclerotic plaque deposits and to safely improve lipid profiles in humans. The company plans to develop multiple applications for its patents-pending therapies in market sectors that include: cardiovascular disease, stroke, peripheral artery disease, dementia and Alzheimer's, and erectile dysfunction, all of which have been linked to atherosclerosis.
For more information visit AtheroNova.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net